

Bernard A Fox

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4527353/publications.pdf>

Version: 2024-02-01

56
papers

6,958
citations

185998

28
h-index

205818

48
g-index

60
all docs

60
docs citations

60
times ranked

11278
citing authors

#	ARTICLE	IF	CITATIONS
1	Cancer microenvironment and genomics: evolution in process. <i>Clinical and Experimental Metastasis</i> , 2022, 39, 85-99.	1.7	11
2	Cumulative suppressive index as a predictor of relapse free survival and overall survival in Human Papilloma Virus –negative oral squamous cell carcinomas with negative resection margins. <i>Head and Neck</i> , 2021, 43, 568-576.	0.9	3
3	The State of Melanoma: Emergent Challenges and Opportunities. <i>Clinical Cancer Research</i> , 2021, 27, 2678-2697.	3.2	53
4	Intratumoral Plasmid IL12 Expands CD8+ T Cells and Induces a CXCR3 Gene Signature in Triple-negative Breast Tumors that Sensitizes Patients to Anti–PD-1 Therapy. <i>Clinical Cancer Research</i> , 2021, 27, 2481-2493.	3.2	33
5	Neoadjuvant anti-OX40 (MEDI6469) therapy in patients with head and neck squamous cell carcinoma activates and expands antigen-specific tumor-infiltrating T cells. <i>Nature Communications</i> , 2021, 12, 1047.	5.8	96
6	Abstract CT139: Intratumoral oncolytic virus V937 in combination with pembrolizumab (pembro) in patients (pts) with advanced melanoma: Updated results from the phase 1b CAPRA study. <i>Cancer Research</i> , 2021, 81, CT139-CT139.	0.4	8
7	SARS-CoV-2 Antibodies Detected in Mother’s Milk Post-Vaccination. <i>Journal of Human Lactation</i> , 2021, 37, 492-498.	0.8	59
8	Neoadjuvant immunotherapy is reshaping cancer management across multiple tumour types: The future is now!. <i>European Journal of Cancer</i> , 2021, 152, 155-164.	1.3	21
9	No time to die: the consensus immunoscore for predicting survival and response to chemotherapy of locally advanced colon cancer patients in a multicenter international study. <i>Oncolmmunology</i> , 2020, 9, 1826132.	2.1	10
10	Perspectives in melanoma: meeting report from the “Melanoma Bridge”(December 5th–7th, 2019,) Tj ETQq0,0 0 rgBT /Overlock	1.8	5
11	Multicenter International Society for Immunotherapy of Cancer Study of the Consensus Immunoscore for the Prediction of Survival and Response to Chemotherapy in Stage III Colon Cancer. <i>Journal of Clinical Oncology</i> , 2020, 38, 3638-3651.	0.8	130
12	Heterodimeric IL-15 delays tumor growth and promotes intratumoral CTL and dendritic cell accumulation by a cytokine network involving XCL1, IFN- β , CXCL9 and CXCL10. , 2020, 8, e000599.		69
13	Future Research Goals in Immunotherapy. <i>Surgical Oncology Clinics of North America</i> , 2019, 28, 505-518.	0.6	2
14	Multispectral Fluorescence Imaging Allows for Distinctive Topographic Assessment and Subclassification of Tumor-Infiltrating and Surrounding Immune Cells. <i>Methods in Molecular Biology</i> , 2019, 1913, 13-31.	0.4	12
15	Coordinated responses to individual tumor antigens by IgG antibody and CD8+ T cells following cancer vaccination. , 2018, 6, 27.		17
16	PD-L1 expression with immune-infiltrate evaluation and outcome prediction in melanoma patients treated with ipilimumab. <i>Oncolmmunology</i> , 2018, 7, e1405206.	2.1	43
17	Tumor cell-released autophagosomes (TRAPs) promote immunosuppression through induction of M2-like macrophages with increased expression of PD-L1. , 2018, 6, 151.		110
18	Autophagosome-based strategy to monitor apparent tumor-specific CD8 T cells in patients with prostate cancer. <i>Oncolmmunology</i> , 2018, 7, e1466766.	2.1	3

#	ARTICLE	IF	CITATIONS
19	Perspectives in immunotherapy: meeting report from the Immunotherapy Bridge (29-30 November, 2017,) Tj ETQq1 1 0.784314 rgBT	1.0	12
20	Co-expression of CD39 and CD103 identifies tumor-reactive CD8 T cells in human solid tumors. Nature Communications, 2018, 9, 2724.	5.8	578
21	Novel frontiers in detecting cancer metastasis. Clinical and Experimental Metastasis, 2018, 35, 403-412.	1.7	8
22	International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study. Lancet, The, 2018, 391, 2128-2139.	6.3	1,487
23	Neoadjuvant anti-OX40 (MEDI6469) prior to surgery in head and neck squamous cell carcinoma.. Journal of Clinical Oncology, 2018, 36, 6011-6011.	0.8	22
24	Immunoprofiling as a predictor of patientâ€™s response to cancer therapyâ€™ promises and challenges. Current Opinion in Immunology, 2017, 45, 60-72.	2.4	39
25	Ubiquitinated Proteins Isolated From Tumor Cells Are Efficient Substrates for Antigen Cross-Presentation. Journal of Immunotherapy, 2017, 40, 155-163.	1.2	5
26	Heterodimeric IL15 Treatment Enhances Tumor Infiltration, Persistence, and Effector Functions of Adoptively Transferred Tumor-specific T Cells in the Absence of Lymphodepletion. Clinical Cancer Research, 2017, 23, 2817-2830.	3.2	32
27	Relationships matter in oral cancer: will single-stain immunohistochemistry become irrelevant in the age of multispectral imaging?. Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology, 2017, 124, 517-518.	0.2	0
28	Timing of PD-1 Blockade Is Critical to Effective Combination Immunotherapy with Anti-OX40. Clinical Cancer Research, 2017, 23, 6165-6177.	3.2	249
29	Multiparametric immune profiling in HPVâ€™ oral squamous cell cancer. JCI Insight, 2017, 2, .	2.3	149
30	The need for a network to establish and validate predictive biomarkers in cancer immunotherapy. Journal of Translational Medicine, 2017, 15, 223.	1.8	25
31	STING expression and response to treatment with STING ligands in premalignant and malignant disease. PLoS ONE, 2017, 12, e0187532.	1.1	30
32	Multispectral Imaging of T and B Cells in Murine Spleen and Tumor. Journal of Immunology, 2016, 196, 3943-3950.	0.4	63
33	Combinational Immunotherapy with Allo-DRibbles Vaccines and Anti-OX40 Co-Stimulation Leads to Generation of Cross-Reactive Effector T Cells and Tumor Regression. Scientific Reports, 2016, 6, 37558.	1.6	28
34	Immunodynamics: a cancer immunotherapy trials network review of immune monitoring in immuno-oncology clinical trials. , 2016, 4, 15.		67
35	Glimpse into the future: harnessing autophagy to promote anti-tumor immunity with the DRibbles vaccine. , 2016, 4, 25.		30
36	Novel technologies and emerging biomarkers for personalized cancer immunotherapy. , 2016, 4, 3.		183

#	ARTICLE	IF	CITATIONS
37	Validation of the Immunoscore (IM) as a prognostic marker in stage I/II/III colon cancer: Results of a worldwide consortium-based analysis of 1,336 patients.. Journal of Clinical Oncology, 2016, 34, 3500-3500.	0.8	57
38	Dynamics of tumor response in advanced melanoma patients treated with Coxsackievirus A21.. Journal of Clinical Oncology, 2016, 34, 9553-9553.	0.8	2
39	Multispectral imaging of formalin-fixed tissue predicts ability to generate tumor-infiltrating lymphocytes from melanoma. , 2015, 3, 47.		119
40	Editorial: Advances in Combination Tumor Immunotherapy. Frontiers in Oncology, 2015, 5, 198.	1.3	0
41	Sustained Complete Response to CTLA-4 Blockade in a Patient with Metastatic, Castration-Resistant Prostate Cancer. Cancer Immunology Research, 2014, 2, 399-403.	1.6	38
42	Towards the introduction of the "Immunoscore"™ in the classification of malignant tumours. Journal of Pathology, 2014, 232, 199-209.	2.1	1,151
43	Cross-presentation of viral antigens in dendritic cells leads to efficient activation of virus-specific human memory t cells. Journal of Translational Medicine, 2014, 12, 100.	1.8	28
44	OX40 Is a Potent Immune-Stimulating Target in Late-Stage Cancer Patients. Cancer Research, 2013, 73, 7189-7198.	0.4	410
45	Autophagy-assisted antigen cross-presentation. OncoImmunology, 2012, 1, 976-978.	2.1	48
46	Cancer classification using the Immunoscore: a worldwide task force. Journal of Translational Medicine, 2012, 10, 205.	1.8	676
47	Defining the critical hurdles in cancer immunotherapy. Journal of Translational Medicine, 2011, 9, 214.	1.8	139
48	Tumor-Derived Autophagosome Vaccine: Induction of Cross-Protective Immune Responses against Short-lived Proteins through a p62-Dependent Mechanism. Clinical Cancer Research, 2011, 17, 6467-6481.	3.2	81
49	Tumor-Derived Autophagosome Vaccine: Mechanism of Cross-Presentation and Therapeutic Efficacy. Clinical Cancer Research, 2011, 17, 7047-7057.	3.2	119
50	Recommendations from the iSBTc-SITC/FDA/NCI Workshop on Immunotherapy Biomarkers. Clinical Cancer Research, 2011, 17, 3064-3076.	3.2	108
51	Cross-presentation of tumor associated antigens through tumor-derived autophagosomes. Autophagy, 2009, 5, 576-577.	4.3	56
52	Therapeutic T cells induce tumor-directed chemotaxis of innate immune cells through tumor-specific secretion of chemokines and stimulation of B16BL6 melanoma to secrete chemokines. Journal of Translational Medicine, 2007, 5, 56.	1.8	14
53	Immunotherapy for melanoma: The good, the bad, and the future. Current Oncology Reports, 2005, 7, 383-392.	1.8	8
54	Tumour-induced polarization of tumour vaccine-draining lymph node T cells to a type 1 cytokine profile predicts inherent strong immunogenicity of the tumour and correlates with therapeutic efficacy in adoptive transfer studies. Immunology, 2003, 108, 409-419.	2.0	33

#	ARTICLE	IF	CITATIONS
55	Adjuvant Immunization of HLA-A2 ⁺ Positive Melanoma Patients With a Modified gp100 Peptide Induces Peptide-Specific CD8 ⁺ T-Cell Responses. <i>Journal of Clinical Oncology</i> , 2003, 21, 1562-1573.	0.8	107
56	Identification of Tumor-Specific Antibodies in Patients With Breast Cancer Vaccinated With Gene-Modified Allogeneic Tumor Cells. <i>Journal of Immunotherapy</i> , 2003, 26, 163-170.	1.2	32